Literature DB >> 8372608

Current tools in the diagnosis of pituitary tumours.

S W Lamberts1, W W de Herder, D J Kwekkeboom, A J vd Lely, F R Nobels, E P Krenning.   

Abstract

Pituitary tumours result in hypersecretion of different hormones which can be used in diagnosis. Prolactinomas can be diagnosed by measurement of prolactin serum concentration. Prolactin concentrations of > 150 to 200 micrograms/l are invariably due to macroprolactinoma. Lower levels may indicate microprolactinoma or a peripituitary tumour. Computed tomography scans visualize (micro)prolactinomas of 3 mm. Diagnosis of acromegaly is now based on measurement of serum IGF-I concentration. IGF-I levels correlate with the old test which measured insufficient suppression of GH levels to < 2 micrograms/l in response to oral glucose load. Most endocrine tumours have somatostatin receptors, allowing visualization with radiolabelled somatostatin analogues. 111In-diethylenetriaminopentaacetic acid-octreotide allows normal pituitary and somatostatin positive tumours to be visualized. A positive scan is predictive of good response to octreotide therapy. Cushing's syndrome is diagnosed by ecchymoses, myopathy, hypertension, and by measurement of the overnight 1 mg dexamethasone suppression test, urine cortisol levels and the diurnal cortisol rhythm. Clinically nonfunctioning macroadenomas in post-menopausal women often do not immunostain for gonadotropins. Serum gonadotropin levels are not elevated, although they do release gonadotropins or subunits in vitro. Diagnosis is assisted by TRH administration which increases serum gonadotropins or subunits, especially LH-beta.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372608

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

Review 1.  Somatostatin analogue treatment of neuroendocrine tumours.

Authors:  W W de Herder; A J van der Lely; S W Lamberts
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

2.  111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.

Authors:  P Legovini; E De Menis; D Billeci; B Conti; P Zoli; N Conte
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

Review 3.  Endocrine inactive and gonadotroph adenomas: diagnosis and management.

Authors:  M Losa; P Mortini; R Barzaghi; A Franzin; M Giovanelli
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.